X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (446) 446
female (424) 424
oncology (380) 380
breast neoplasms - drug therapy (361) 361
antineoplastic combined chemotherapy protocols - therapeutic use (358) 358
breast cancer (350) 350
index medicus (340) 340
middle aged (319) 319
adult (294) 294
breast neoplasms - pathology (283) 283
neoadjuvant therapy (263) 263
preoperative chemotherapy (241) 241
cancer (240) 240
aged (238) 238
surgical adjuvant breast (219) 219
chemotherapy (216) 216
neoadjuvant chemotherapy (196) 196
treatment outcome (187) 187
medicine & public health (176) 176
neoplasm staging (167) 167
surgery (150) 150
adjuvant treatment (145) 145
breast neoplasms - surgery (144) 144
prognosis (137) 137
docetaxel (136) 136
chemotherapy, adjuvant (132) 132
taxoids - administration & dosage (132) 132
cyclophosphamide (129) 129
therapy (120) 120
cyclophosphamide - administration & dosage (118) 118
project protocol b-27 (114) 114
doxorubicin (108) 108
care and treatment (105) 105
doxorubicin - administration & dosage (88) 88
retrospective studies (86) 86
disease-free survival (83) 83
breast neoplasms - mortality (80) 80
research (78) 78
pathological complete response (76) 76
surgical oncology (76) 76
receptor, erbb-2 - metabolism (75) 75
follow-up studies (74) 74
trastuzumab (73) 73
breast neoplasms - metabolism (72) 72
epirubicin - administration & dosage (72) 72
fluorouracil - administration & dosage (71) 71
randomized-trial (71) 71
anthracyclines (70) 70
carcinoma (70) 70
neoadjuvant therapy - methods (70) 70
antineoplastic combined chemotherapy protocols - adverse effects (69) 69
mastectomy (68) 68
paclitaxel (66) 66
survival (66) 66
women (64) 64
cancer patients (63) 63
trial (63) 63
health aspects (61) 61
carcinoma, ductal, breast - drug therapy (58) 58
paclitaxel - administration & dosage (58) 58
analysis (57) 57
lymphatic metastasis (57) 57
survival rate (57) 57
receptors, estrogen - metabolism (55) 55
biopsy (54) 54
young adult (52) 52
tumors (51) 51
antineoplastic combined chemotherapy protocols - administration & dosage (50) 50
cancer research (49) 49
clinical trials (49) 49
prospective studies (49) 49
breast neoplasms - therapy (46) 46
combined modality therapy (46) 46
sentinel lymph node biopsy (44) 44
cancer therapies (43) 43
axilla (42) 42
drug therapy (42) 42
hematology, oncology and palliative medicine (42) 42
induction chemotherapy (42) 42
oncology, experimental (41) 41
receptors, progesterone - metabolism (41) 41
carcinoma, ductal, breast - pathology (40) 40
carcinoma, lobular - drug therapy (40) 40
drug administration schedule (40) 40
tumor response (40) 40
breast neoplasms - genetics (39) 39
aged, 80 and over (38) 38
mastectomy, segmental (38) 38
lymph nodes - pathology (37) 37
research article (35) 35
epirubicin (34) 34
survival analysis (34) 34
deoxycytidine - analogs & derivatives (33) 33
kaplan-meier estimate (33) 33
pathological response (33) 33
predictive value of tests (33) 33
lymph node excision (32) 32
pathology (32) 32
patient outcomes (32) 32
biomarkers, tumor - metabolism (31) 31
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 15, pp. 1796 - 1804
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 4, pp. 310 - 320
The addition of bevacizumab to neoadjuvant combination chemotherapy significantly increased the percentage of patients with a pathological complete response.... 
PROJECT PROTOCOL B-27 | TRIAL | MEDICINE, GENERAL & INTERNAL | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | THERAPY | DOXORUBICIN PLUS CYCLOPHOSPHAMIDE | PHASE-III | DISEASE | DOCETAXEL | PACLITAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bevacizumab | Angiogenesis Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Mastectomy, Segmental | Adult | Female | Neoadjuvant Therapy | Angiogenesis Inhibitors - adverse effects | Doxorubicin - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Logistic Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease Progression | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Receptor, ErbB-2 | Deoxycytidine - analogs & derivatives | Drugs | Chemotherapy | Usage | Patient outcomes | Breast cancer | Product/Service Evaluations | Drug therapy | Cancer | Heart | Mucositis | Gemcitabine | Review boards | Body weight | Cancer therapies | Antimetabolites | Doxorubicin | ErbB-2 protein | Patients | Feet | Metastases | Cyclophosphamide | Epidermal growth factor | Ventricle | Taxanes | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 05/2015, Volume 22, Issue 5, pp. 1425 - 1433
Journal Article